Pipeline

MMB pipeline addresses significant medically unmet needs in immuno-oncology by directly targeting T cells, immune checkpoints and tumor micro-environment.

MediMabBio’s pipelines include first-in-class antibody immunotherapies, which target an immune checkpoint inhibitor (ICI) and antagonistic or agonistic activity on the signaling receptor in different sets of immune cells. This is expected to induce anti-tumor immunity by stimulating effector T cells and inhibiting regulatory T cell activity. In order to modulate tumor microenvironment with optimized specificity and functionality, the company focuses on generating Neokine-tethered immunotherapeutic antibody, which has been developed through computational modelling and well-established MMB screening system.

Product Indication Therapeutic Modality Discovery Lead Optimization Preclinical Efficacy CMC development IND-enabling Phase I
Oncology
MMB101 Immuno- Oncology Monoclonal Antibody
MMB102 Immuno- Oncology Monoclonal Antibody
MMB201 Immuno- Oncology Fusion Antibody
MMB202 Immuno- Oncology Fusion Antibody
Inflammatory Disease
MMB301 Autoimmune Disease Neutralizing Antibody
Infectious Disease
MMB401 Covid-19 Neutralizing Antibody
Product Indication Discovery Lead Optimization Preclinical Efficacy CMC Development
Oncology
MMB101 Immuno Oncology
MMB102 Immuno Oncology
MMB201 Immuno Oncology
MMB202 Immuno Oncology
Inflammatory Disease
MMB301 Autoimmune Disease
Infectious Disease
Covid-19 Autoimmune Disease
Product Discovery Lead
Optimization
Preclinical
Efficacy
CMC
Development
Oncology
MMB101
MMB102
MMB201
MMB202
Inflanmmatory Disease
MMB301
Infectious Disease
MMB401